Neal D. Shore, MD, FACS of Carolina Urologic Research Center explains how BRCA1 and BRCA2 genetic testing are significantly changing how prostate cancer should be treated. He believes that guidelines are a bit premature, but nonetheless, they are helping with therapy options for patients. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
BRCA1 and BRCA2 Genetic Testing are Dramatically Changing Prostate Cancer Treatment Options
